Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Praxis Precision Medicines will report Q3 2026 financial results before market open on Monday, November 9, 2026. The company also announced an Investor Day in New York on November 12 at 8:00 a.m. ET, covering commercial strategy and launch readiness for ulixacaltamide (Essential Tremor) and relutrigine (SCN2A/SCN8A DEE), both currently under FDA review.
Key figures
- Investor day
- 2026-11-12, New York
- Earnings date
- 2026-11-09
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.